Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. (Q39829999)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

corneal neovascularization

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Irit Bahar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Penny McAllum

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

David Rootman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Allan Slomovic

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

23-28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

Pathogenesis of pterygium

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Histology of pterygium: an electron microscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

The pathogenesis of pterygia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Mechanistic insights on the inhibition of tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02713680701799101

10.1080/02713680701799101

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214740%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference